Last reviewed · How we verify

NCT04890444: CASE

China Adrenal Disease Registry

Recruiting now Last updated 14 February 2022
What this trial tests

trial in Cushing Syndrome in 2,000 participants. Currently enrolling.

Timeline
1 June 2021
Primary endpoint
30 April 2026
30 April 2026

Quick facts

Lead sponsorShanghai Jiao Tong University School of Medicine
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date1 June 2021
Primary completion30 April 2026
Estimated completion30 April 2026
Sites1 location across China

Conditions studied

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 16 to 75, any sex, with Cushing Syndrome or Aldosteronism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide. In order to meet all the therapeutic challenges in adrenal disease in China, CASE was founded in 2020. The objective of CASE is to launch an adrenal disease management model based on the Internet health information platform which allows the application and evaluation of adrenal disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of adrenal disease, diagnosis, and treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cushing Syndrome

Currently open trials in the same condition.

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04890444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing